Rapamycin

Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.

Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.

Trial registry update: COMPLETED. No results reported in the supplied registry record.

Trial registry update: NOT_YET_RECRUITING. No results reported in the supplied registry record.

Trial registry update: TERMINATED. No results reported in the supplied registry record.

Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.

Trial registry update: TERMINATED. No results reported in the supplied registry record.

Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.

Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.

Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.

Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.

Trial registry update: TERMINATED. Results are posted in the registry; assessment pending.

Trial registry update: COMPLETED. No results reported in the supplied registry record.

Trial registry update: COMPLETED. No results reported in the supplied registry record.

Trial registry update: RECRUITING. No results reported in the supplied registry record.

Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.

Trial registry update: RECRUITING. No results reported in the supplied registry record.

Trial registry update: TERMINATED. No results reported in the supplied registry record.

Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.

Trial registry update: RECRUITING. No results reported in the supplied registry record.

Trial registry update: RECRUITING. No results reported in the supplied registry record.

Trial registry update: RECRUITING. No results reported in the supplied registry record.

Trial registry update: RECRUITING. No results reported in the supplied registry record.

Trial registry update: COMPLETED. Results are posted in the registry; assessment pending.

Trial registry update: RECRUITING. No results reported in the supplied registry record.

Trial registry update: ACTIVE_NOT_RECRUITING. No results reported in the supplied registry record.

Trial registry update: COMPLETED. No results reported in the supplied registry record.

This systematic review examined mTOR signaling as a hub coordinating aging processes across genetic, experimental, and translational studies. In model organisms, mTOR pathway inhibition shows causal effects on lifespan regulation, whereas human data remain predominantly observational and associative. The review identifies mTOR as an integrative node linking multiple aging hallmarks and notes that major geroprotective interventions—including autophagy activation, dietary changes, physical activity, and senotherapeutics—partly converge on but also diverge from mTOR pathway modulation.

A randomised, double-masked, parallel group study designed to assess the safety and efficacy of oral everolimus (an mTOR inhibitor in the rapamycin class) alone or combined with lucentis in patients with neovascular age-related macular degeneration. No efficacy or safety results were reported in the material provided.

A Phase 1/2 randomized controlled trial evaluated sirolimus (rapamycin) administered via different injection routes in patients with newly diagnosed, treatment-naive sub-foveal choroidal neovascularization secondary to age-related macular degeneration. The study assessed safety and efficacy outcomes, though specific effect sizes and patient numbers were not reported in the provided abstract.

This phase 2 randomized controlled trial assessed whether adding ocular sirolimus (rapamycin) to Lucentis improved outcomes compared to Lucentis plus placebo in patients with subfoveal choroidal neovascularization secondary to age-related macular degeneration. The study evaluated safety and efficacy, though specific findings, sample size, and effect sizes are not reported in the available material.

This was a phase 2 RCT planned to enroll 50 people with geographic atrophy from age-related macular degeneration, randomized to receive monthly intravitreal sirolimus (440 μg) injections or sham treatment for up to 24 months. The study was terminated in May 2014 before completion due to safety concerns, with no efficacy results reported.

This randomised controlled trial evaluated whether infliximab, sirolimus, or daclizumab combined with standard AMD care would prevent new blood vessel growth in the eye compared to observation alone. The study enrolled participants aged 55+ with AMD and drusen >63 μm, with baseline vision between 20/20 and 20/400. Participants received one of three treatments or observation only, with evaluations at 6 months including retinal imaging, angiography, and blood tests.

This is a two-phase study protocol: phase 1 is a dose-escalation pilot in 18 older adults (≥60 years) with coronary artery disease undergoing cardiac rehabilitation, receiving oral rapamycin at 0.5, 1, or 2mg daily with measurement of frailty, quality of life, and senescent biomarkers; phase 2 is a planned RCT comparing exercise alone versus exercise plus low-dose rapamycin. No results are reported here—this is a protocol describing the planned intervention and endpoints.

This Phase 2 randomized controlled trial compared intravitreal sirolimus injections to anti-VEGF treatment in patients with wet age-related macular degeneration who had persistent retinal edema despite previous anti-VEGF therapy. The study was conducted at a single site with subject masking. Specific efficacy and safety results were not reported in the abstract provided.

This was a translational RCT investigating whether rapamycin, an FDA-approved immunosuppressant, could improve immune responsiveness, cognition, and functional outcomes in elderly adults aged 70-95. The abstract describes the trial design and rationale based on preclinical findings in mice but does not report results, sample size, or effect sizes from the human trial.

This pilot study tested whether sirolimus, injected under the outer layer of the eye, was safe and could preserve vision in patients with bilateral geographic atrophy (advanced dry AMD). Participants with visual acuity between 20/20 and 20/400 received sirolimus injections every 3 months over 2 to 3 years, with regular eye examinations, imaging, and blood tests to monitor safety and vision outcomes.

This pilot study assessed whether intravitreal sirolimus injections are safe and can help preserve vision in patients with bilateral geographic atrophy (GA), an advanced form of dry age-related macular degeneration. Participants aged 56 years or older with GA received sirolimus injections into one eye every 2 months over 1 year, with follow-up eye exams conducted at 8 or more visits. The abstract does not report the sample size, outcomes measured, or findings.

This was a randomized controlled trial investigating whether topical rapamycin ointment applied to forearms could induce epigenetic changes in skin tissue. The study specifically tested whether the drug could reverse inflammation and reset epigenetic aging markers locally in the skin.

Researchers examined whether rapamycin could reduce malignant markers and the number of aberrant mammary stem/progenitor cells (MaSCs) in surgical specimens. The study found that rapamycin did reduce both malignant markers and aberrant MaSCs numbers. This was an ex vivo or tissue-based study design.

PEARL was a prospective, double-blind, placebo-controlled randomized trial examining rapamycin's safety and efficacy in reducing clinical measures of aging in older adults. The abstract does not report the sample size, which study arms were compared, what outcome measures were used, or what effects were observed.

A retrospective study compared blood rapamycin levels achieved with compounded versus generic formulations in older adults. The study aimed to determine the relative bioavailability ratio between the two formulations and their relative efficacy in raising rapamycin levels. The specific findings regarding bioavailability differences were not stated in the provided abstract.

This is a planned RCT that aimed to recruit 16 healthy men over 50 years old to investigate how rapamycin (a mTOR inhibitor) affects muscle mass and function, both as monotherapy and combined with resistance exercise training. The source provided only the study rationale and design intent, with no outcome data reported.

This was a substudy (Substudy E) of a translational trial examining rapamycin's effects in elderly persons aged 70-95. The substudy specifically evaluated rapamycin and cardiac function using cardiac MRI with late gadolinium enhancement (LGE). No results were reported in the abstract provided.

A prospective, randomized, double-blind, placebo-controlled pilot study was proposed to assess whether low-dose rapamycin could delay ovarian aging in women. Animal studies had suggested rapamycin might slow or reverse age-associated pathways. No results, sample size, or effect sizes were reported in the abstract.

This randomized controlled trial enrolled postmenopausal women aged 60-75 years in a 1:1:1:1 design comparing oral everolimus 5 mg weekly, placebo weekly, everolimus plus resistance training (3 hours weekly), or placebo plus resistance training. The study measured bone formation, muscle function, bone and muscle protein turnover, and quality of life through imaging, biopsies, blood samples, and functional testing across 5-7 visits. No results are reported in the material provided.

This 24-week randomized controlled trial enrolled 136 postmenopausal women (aged 45-60) assigned to control, exercise training, everolimus (5 mg weekly), or combined treatment. The primary outcome was percentage change in bone formation marker P1NP at week 24, with secondary outcomes including bone resorption marker CTX, bone mineral density, bone structure, muscle function, and postural balance. The study does not report the effect sizes or results for any outcome.

RAP PAC is a randomised trial designed to identify safe weekly doses of sirolimus or everolimus in adults aged 55-89 without overt chronic disease. Participants receive 6 weeks of treatment at 5, 10, or 15 mg once weekly. This is a protocol description; no efficacy or safety outcomes have been reported.

RESTOR was an exploratory pharmacokinetic/pharmacodynamic study that tested two mTOR inhibitors (rapamycin and everolimus) in healthy older adults. The study aimed to identify doses that could safely inhibit mTOR to levels seen in young people, with attention to potential sex differences in optimal dosing. No efficacy outcomes or clinical benefits were reported.

This was a randomized controlled trial designed to characterize how rapamycin is processed and acts in the body in older adults. The study aimed to generate foundational pharmacokinetic and pharmacodynamic data needed to inform future clinical trials of mTOR inhibitors in aging-related conditions. No efficacy outcomes, sample sizes, or effect sizes were reported in the available material.

This was a randomized controlled trial proposed to test whether rapamycin (sirolimus) could slow aging processes and reduce biomarkers of aging in older adults. The abstract describes the study design, theoretical rationale based on mTOR pathway inhibition, and stated hypothesis that rapamycin may impact aging and chronic disease development. No results, sample size, or effect measures are reported.

This randomized controlled trial tested whether 24 weeks of mTORC1 inhibition via everolimus (0.5 mg daily or 5 mg weekly) could improve physiological and molecular hallmarks of aging. Participants aged 55-80 with insulin resistance or prediabetes received active treatment; a younger comparison group (ages 18-35) did not receive intervention.

This Phase 1b RCT assessed the safety and feasibility of combining exercise, spermidine supplementation, and either rapamycin or lamivudine in participants. The study evaluated whether this multi-component intervention could be delivered as designed and was tolerated, as a precursor to testing effects on inflammation and aging markers.

This randomized controlled trial evaluated the safety, feasibility, and preliminary efficacy of low-dose daily rapamycin (1 mg) or fasting-mimicking diet (FMD) compared to placebo over 8 weeks in middle-aged adults carrying the APOE ε4 allele, a genetic risk factor for Alzheimer's disease. The study aimed to assess outcomes related to body, brain, and longevity in this at-risk population. No results of the intervention were reported in the abstract provided.

A preclinical study exposed rats to cigarette smoke for 8 weeks and treated human bronchial epithelial cells with cigarette smoke extract to model COPD-related cellular senescence. Rapamycin (an autophagy activator) reversed impaired autophagic flux and cellular senescence markers in both in vivo and in vitro models, while the AhR antagonist CH223191 and ROS scavenger NAC similarly restored autophagy and reduced senescence.

This preclinical study examined how Hepassocin (HPS), a hepatokine, affects liver aging and regeneration in mice. Aged HPS-knockout mice showed increased cellular senescence, impaired autophagy, and severely compromised liver regeneration after partial hepatectomy, with these deficits reversible by AMPK activation. The authors identified a signaling pathway (ANXA2-ERK-p90RSK-LKB1) through which HPS activates AMPK, and demonstrated that exogenous HPS improved regenerative outcomes in aged wild-type mice.

This systematic review examined pharmacological interventions targeting aging pathways, including metformin, from literature published January 2010–May 2026. Metformin and rapamycin had among the most extensive preclinical and translational evidence, but the review found that clinical evidence for broadly applicable geroprotection remains limited. The authors emphasize a substantial gap between mechanistic plausibility and clinically validated geroprotection in humans.

This is a randomized controlled trial protocol comparing four groups (control, metformin alone, metformin plus rapamycin, and metformin plus naltrexone) in patients discontinuing GLP-1 receptor agonists. The study aims to assess whether these interventions reduce weight regain over six months post-cessation and improve metabolic markers. No results have been reported; this appears to be a study design document rather than outcome data.

This was a 90-day randomized controlled pilot trial comparing three arms: control, multi-therapy (including metformin, naltrexone, B12, and NAD+), and comprehensive therapy (including metformin, rapamycin, naltrexone, B12, NAD+, GSH, and other supplements). The study enrolled up to 30 subjects (approximately 10 per arm) to assess effects on longevity-related outcomes. Effect sizes were not reported.